Molecular marker related to gastric cancer nerve invasion and application thereof
Through the PPP3R1 gene as a molecular marker, the diagnosis and prediction problems of gastric cancer nerve invasion are solved, and effective evaluation of the prognosis of gastric cancer patients and the provision of treatment strategies are achieved.
Patent Information
- Application Number
- CN202411367163.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively diagnose and predict the incidence and prognosis of gastric cancer nerve invasion, and there is relatively little research on gastric cancer nerve invasion.
The PPP3R1 gene was proposed as a molecular marker of gastric cancer nerve invasion. The correlation between its expression level and the incidence and prognosis of nerve invasion in patients with gastric cancer was verified through experiments, and reagents and products for diagnosis and treatment were developed.
The high expression of PPP3R1 gene is related to a good prognosis of gastric cancer, which can effectively predict the incidence of nerve invasion and overall survival in patients with gastric cancer, provide new diagnostic and treatment strategies, and improve the prognosis effect of gastric cancer.
Smart Images

Figure CN118957079A_ABST
Abstract
Description
Technical Field
[0001] The present invention specifically relates to a molecular marker for gastric cancer nerve invasion and application thereof, and belongs to the technical field of biomedicine. Background Art
[0002] Gastric cancer (GC) is one of the most common malignant tumors in the world. Gastric cancer is a disease affected by multiple factors, including environmental and genetic factors. Due to the hidden nature of gastric cancer, most gastric cancer patients are already in the middle or late stages when they are discovered, and the treatment effect is poor. As the incidence of gastric cancer increases year by year, the median age of diagnosis is already 70 years old.
[0003] Perineural invasion (PNI) is the process by which malignant tumors invade nerves and is an important clinical pathological feature of malignant tumors such as pancreatic cancer, prostate cancer, colorectal cancer, and gastric cancer. PNI can be observed in the absence of vascular or lymphatic infiltration and can be the only way for tumor metastasis and spread. It is closely related to high local recurrence rate, poor prognosis, high incidence of metastatic tumors, and cancer pain.
[0004] There is increasing evidence that PNI has a high incidence in patients with gastric cancer (GC). PNI is an independent prognostic factor affecting disease-free survival and overall survival in patients with radical resection of GC, and can be used to predict the benefit of adjuvant chemotherapy in GC patients. Whole genome sequencing and bioinformatics analysis of gastric cancer have shown that axon guidance genes are often mutated in PNI-positive GC patients and affect their survival, indicating that axon guidance genes can be used as potential targets for the diagnosis and / or treatment of gastric cancer neural invasion. However, most studies on axon guidance genes in gastric cancer focus on proliferation, migration and invasion, and research on gastric cancer neural invasion is still very scarce and needs further exploration. Summary of the invention
[0005] In view of some deficiencies in the prior art, the present invention provides a molecular marker related to gastric cancer neural invasion and its application. The present invention provides the PPP3R1 gene related to gastric cancer neural invasion, which has important value in predicting the incidence of neural invasion (PNI) and overall survival of GC patients and can be used as a molecular marker for gastric cancer neural invasion.
[0006] To achieve the above purpose, the technical solution provided by the present invention is as follows:
[0007] The present invention first provides a PPP3R1 gene related to gastric cancer nerve invasion, and the nucleotide sequence of the PPP3R1 gene is shown in SEQ ID No: 1.
[0008] The present invention further provides a molecular marker related to gastric cancer nerve invasion, the molecular marker comprising the PPP3R1 gene, the nucleotide sequence of the PPP3R1 gene being as shown in SEQ ID No: 1; the nucleotide sequence of the mRNA of the PPP3R1 gene being as shown in SEQ ID No: 2; the amino acid sequence of the protein encoded by the PPP3R1 gene being as shown in SEQ ID No: 3.
[0009] The present invention verifies through experiments that the expression level of the PPP3R1 gene is negatively correlated with the incidence of nerve invasion in gastric cancer (GC) patients; and the expression level of the PPP3R1 gene is positively correlated with a good prognosis in gastric cancer patients.
[0010] The present invention also provides a reagent for detecting the PPP3R1 gene or the molecular marker.
[0011] The present invention also provides the use of the gene, the molecular marker or the reagent in preparing a product for diagnosing, detecting and prognosticating gastric cancer nerve invasion, wherein the product includes a kit; wherein the prognostic judgment is that the higher the expression level of the PPP3R1 gene, the better the prognosis of gastric cancer.
[0012] The present invention also provides the use of the gene, the molecular marker or the reagent in preparing a product for treating gastric cancer nerve invasion.
[0013] The present invention also provides the use of an agent for inhibiting or knocking down the expression of the PPP3R1 gene or the molecular marker of the present invention in preparing an in vitro neural invasion model, wherein the agent is shRNA, and the nucleotide sequence of the shRNA is shown in SEQ ID No: 5.
[0014] Among them, the in vitro nerve invasion model is a co-culture model of low growth factor matrix gel, dorsal root ganglion (DRG) and tumor cells, in which the tumor cells are in the middle, and the low growth factor matrix gel and dorsal root ganglion are cultured on both sides of the tumor cells respectively; after the in vitro nerve invasion model is established, the tumor invasion index and DRG growth index are used to jointly evaluate the nerve invasion; among them, the tumor invasion index = tumor cell movement distance / initial distance between DRG and tumor cells, DRG growth index = DRG axon growth distance / initial distance between DRG and tumor cells, the higher the tumor invasion index and DRG growth index, the more obvious the nerve invasion.
[0015] The in vivo nerve invasion model was constructed by injecting a gastric cancer cell suspension into the sciatic nerve of mice. The nerve invasion was evaluated based on the mouse sciatic nerve function score (1-4 points, the lower the score, the more obvious the nerve invasion), the sciatic nerve function index (the extended length between the first toe to the fifth toe of the left lower limb when the mouse is standing on all fours, the shorter the length, the more obvious the nerve invasion) and the tumor volume (the larger the tumor, the more obvious the nerve invasion), as well as the invasion of the sciatic nerve by tumor cells observed after immunohistochemical staining.
[0016] The present invention also provides a product for diagnosing, detecting, and prognosing gastric cancer nerve invasion, wherein the product comprises a reagent for detecting the PPP3R1 gene of the present invention, or the molecular marker.
[0017] The present invention also provides a product for treating gastric cancer nerve invasion, wherein the product comprises a reagent for detecting the PPP3R1 gene of the present invention or the molecular marker.
[0018] The beneficial effects of the present invention are as follows:
[0019] (1) The present invention is the first to discover that PPP3R1 can serve as a key axon guidance gene for gastric cancer nerve invasion, and that the expression of the PPP3R1 gene is negatively correlated with the incidence of PNI in gastric cancer.
[0020] (2) The present invention also discloses that PPP3R1 can be used as an independent prognostic factor, and high expression is associated with a good prognosis of gastric cancer, that is, a high expression level of PPP3R1 can predict a good prognosis for gastric cancer patients.
[0021] (3) The present invention also discloses in vivo and in vitro models for gastric cancer PNI and their respective evaluation indicators. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Box plot of the 10 most relevant axon guidance genes in gastric cancer PNI.
[0023] Figure 2 ROC curve of the optimal cutoff value for distinguishing PNI-positive and -negative genes in gastric cancer.
[0024] Figure 3 The figure is a bar graph showing the correlation between the incidence of PNI and axon guidance genes in gastric cancer.
[0025] Figure 4 This is the cox univariate regression analysis of Example 1.
[0026] Figure 5 Kaplan-Meier survival analysis for the ACRG cohort, GSE15459 cohort, GSE34942 cohort, and GSE57303 cohort.
[0027] Figure 6 The relationship between PPP3R1 expression and PNI in gastric cancer patients; Figure 6 A is a typical image of PNI-negative and PNI-positive IHC staining, and the rectangular enlarged part is the nerve; Figure 6 B is the IHC staining score of PPP3R1 (** indicates p<0.01).
[0028] Figure 7 To construct a MFC gastric cancer cell line with PPP3R1 knockdown; Figure 7 A is the immunofluorescence image of MFC gastric cancer cells before and after puromycin selection; Figure 7 B is a WB validation image of MFC knockdown of PPP3R1; Figure 7 C is the WB band quantification graph (* indicates p < 0.05).
[0029] Figure 8 Immunofluorescence staining of S100β and βⅢTublin in DRG.
[0030] Fig. 9 This is a diagram of the in vitro DRG-MFC model, with DRG on the left, tumor cells in the middle, and low-growth factor matrix gel on the right as a blank control.
[0031] Fig.10 Knockdown of PPP3R1 promotes gastric cancer cell neural invasion; Fig.10 A is the image of DRG-MFC in vitro co-culture at 0, 48 and 96 hours (T represents tumor cells and D represents DRG); Fig.10 B is the MFC invasion index and DRG growth index (* indicates p < 0.05).
[0032] Fig.11 This is an image of MFC invading DRG (the red arrow points to MFC, and the left side under the 20x microscope is DRG).
[0033] Fig.12 The images show the sciatic nerve function, tumor volume and immunohistochemistry of mice on day 20.
[0034] Fig.13 This is the anatomical diagram of the tumors in the shPPP3R1 and shNC groups on day 20.
[0035] Fig.14 It is an evaluation index of sciatic nerve function; among them, Fig.14 A is the line graph of sciatic nerve function score; Fig.14 B is the line graph of sciatic nerve function index; Fig.14 C is a line graph of tumor volume; Fig.14 D is a graph showing tumor weight (* indicates p<0.05). DETAILED DESCRIPTION
[0036] In order to enable those skilled in the art to better understand the technical solution of the present invention, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the present invention, but the following embodiments do not limit the protection scope of the present invention.
[0037] In the embodiments of the present invention, those that are not described in detail are all completed by conventional experimental methods. Those processes involved in the embodiments that are not described in detail are all understandable and easily implementable by those skilled in the art based on the product instructions or basic knowledge in the field, and therefore are not described in detail.
[0038] The culture media, reagents, drugs, etc. involved in the embodiments of the present invention can be purchased through conventional channels.
[0039] The sources of the research objects of the present invention include: the gastric cancer transcriptome data of the PPP3R1 gene (ACRG) is from the Gene Expression Database (GEO) of the National Center for Bioinformation of the United States, the data number is GSE62254, and its nucleotide sequence information is shown in SEQ ID No: 1, and the transcriptome database for Kaplan-Meier analysis also includes the GSE15459 cohort (Singapore gastric cancer patient cohort), the GSE34942 cohort (Singapore gastric cancer patient cohort) and the GSE57303 cohort (Chinese gastric cancer patient cohort); the axon guidance gene set is from the Gene Set Enrichment Analysis (GSEA) database, the data number is M5539. The nucleotide sequence of the mRNA of the PPP3R1 gene is shown in SEQ ID No: 2; the amino acid sequence of the protein encoded by the PPP3R1 gene is shown in SEQ ID No: 3.
[0040] Embodiment 1:
[0041] Screening of key axon guidance genes for gastric cancer nerve invasion includes the following technical steps:
[0042] S1. Research subjects:
[0043] A total of 275 gastric cancer patients from the Asian Cancer Research Group (ACRG) were used to screen PNI-related key axon guidance and validate its prognostic role.
[0044] The inclusion criteria for the patients of ACRG described in this example are: 1) pathological diagnosis of gastric malignancy; 2) complete transcriptome data; 3) positive or negative for nerve invasion.
[0045] The exclusion criteria were: 1) overall survival time was 0 or survival data were missing; 2) data on the clinical pathological feature of nerve invasion were missing.
[0046] S2. Data Analysis:
[0047] The chi-square test, Mann-Whitney U test, Student's t test, Fisher's exact test, and Wilcoxon test were used to compare the differences between the groups according to the data characteristics. The optimal cutoff value of the ROC curve, i.e., sensitivity + specificity - 1, was used for high and low PPP3R1 expression levels. The univariate Cox proportional hazard model was used to evaluate prognostic factors and calculate HR and 95% CI. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Bilateral p < 0.05 was considered statistically significant. All statistical analyses and graphics were performed using R, R Bioconductor package, and IBM SPSS Statistics 25 software.
[0048] S3. Key gene screening:
[0049] (1) Clinical data collation:
[0050] The clinical information of the screened ACRG patients was obtained and preprocessed, and a table of clinical pathological characteristics of PNI-positive and PNI-negative patients was compiled, which mainly included five aspects: gender: male or female; age: ≤65 years or >65 years; histological grade: grade I / II or grade III / IV; stage: grade I / II, grade III / IV or other; MS status: microsatellite instability (MSI), microsatellite stability (MS) and mesenchymal–mesenchymal transition (EMT), as shown in Table 1.
[0051] A total of 247 patients were eligible and included in this study, including 88 PNI-positive patients and 159 PNI-negative patients. Compared with PNI-negative patients, PNI-positive patients were more likely to be GC patients aged ≤65 years (52.5 vs. 65.9%, P = 0.037), and the proportion of stage III / IV (51.6 vs. 69.3%, p = 0.007) and histological grade III / IV (49.1 vs. 77.3%, P < 0.001) in PNI-positive GC was increased. In GC, the incidence of PNI was significantly correlated with MS status (P < 0.001), but not with gender (P = 0.901).
[0052] Table 1. Characteristics of ACRG clinical data
[0053] feature Positive for nerve invasion (n=88) Negative for nerve invasion (n=159) P-value age ≤ 65 years 58(65.9) 83(52.2) 0.037 >65 years old 30(34.1) 76(47.8) gender female 27(30.7) 50(31.4) 0.901 male 61(69.3) 109(68.6) Staging I / II 27(30.7) 77(48.4) 0.007 III / IV 61(69.3) 82(51.6) Histological grading I / II 20(22.7) 79(49.7) <0.001 III / IV 68(77.3) 78(49.1) other 0 2(1.2) MS Status MSI 11(12.5) 47(29.5) <0.001 MSS 57(64.8) 99(62.3) EMT 20(22.7) 13(8.2)
[0054] (2) Preliminary screening of key axon guidance genes for nerve invasion in gastric cancer:
[0055] The data obtained in step (1) were used to screen the 10 axon guidance genes most associated with gastric cancer nerve invasion, namely DRYSL2 (p = 0.035), EFNA1 (p = 0.037), GSK3B (p = 0.013), LIMK2 (p = 0.021), NCK1 (p = 0.022), NRP1 (p = 0.007), NTN4 (p = 0.015), PLXNA2 (p = 0.022), PPP3CB (p = 0.007) and PPP3R1 (p = 0.015) ( Figure 1 ). The optimal cutoff value (sensitivity + specificity - 1) for distinguishing gastric cancer PNI positive and negative genes was obtained by ROC curve ( Figure 2 ), the correlation and P value of the above 10 genes with gastric cancer PNI were compared by using the optimal cutoff value. DRYSL2 (p = 0.026), PPP3CB (p = 0.002), NTN4 (p = 0.005), NRP1 (p = 0.001) and PLXNA2 (p = 0.008) were positively correlated with the incidence of gastric cancer PNI, EFNA1 (p = 0.001), GSK3B (p = 0.003), NCK1 (p = 0.001), PPP3R1 (p < 0.001), LIMK2 (p = 0.001) were negatively correlated with the incidence of gastric cancer PNI, and the p value was < 0.05. Among them, the p value of PPP3R1 was the smallest, indicating that the expression of PPP3R1 was most strongly correlated with gastric cancer PNI, and the incidence of PNI in gastric cancer patients with high expression of PPP3R1 was low ( Figure 3 , Table 2).
[0056] Table 2. PNI incidence and gene expression
[0057]
[0058]
[0059] (3) Prognostic correlation analysis:
[0060] The 10 axon guidance genes obtained in step (2) were subjected to Cox univariate regression analysis, and the P value was converted to -Log10 (P value). HR < 1.0 indicated that the gene expression level was positively correlated with the prognosis of gastric cancer patients, HR > 1.0 indicated a negative correlation, and HR = 1.0 indicated no correlation.
[0061] Depend on Figure 4The results of the cox univariate regression analysis showed that PPP3R1, NCK1 and LIMK2 were positively correlated with the prognosis of gastric cancer patients, while PLXNA2, DRYSL2, EFNA1, GSK3B, NRP1, NTN4, PLXNA2 and PPP3CB were negatively correlated with the prognosis of gastric cancer patients. It can be seen that PPP3R1 can be used as an independent prognostic factor for gastric cancer patients, and the higher its expression level, the better the prognosis of gastric cancer patients.
[0062] Kaplan-Meier survival analysis was performed on the ACRG, GSE15459, GSE34942, and GSE57303 cohorts. In the above four cohorts, gastric cancer patients with high and low PPP3R1 expression showed good prognosis, with p values of 0.00057, 0.017, 0.012, and 0.024, respectively. Figure 5 ), further verified that PPP3R1 can be used as an independent predictor of gastric cancer, and high expression of PPP3R1 is positively correlated with a good prognosis of gastric cancer patients.
[0063] Embodiment 2:
[0064] Immunohistochemistry was used to verify the correlation between PPP3R1 and gastric cancer neural invasion, including the following technical steps:
[0065] S1. Research subjects:
[0066] Methods: Twenty-two and 26 patients with negative and positive nerve invasion of gastric cancer were randomly selected from the Department of Pathology of the Affiliated Hospital of Jiangsu University (AHJU) from January 2019 to December 2020, respectively.
[0067] The patients with negative and positive gastric cancer nerve invasion in the Department of Pathology of the Affiliated Hospital of Jiangsu University (AHJU) described in this example were screened according to the following screening criteria:
[0068] 1) January 1, 2019 to December 31, 2020;
[0069] 2) Pathological diagnosis of gastric cancer;
[0070] 3) Sufficient pathological tissue for immunohistochemical staining;
[0071] 4) Pathological diagnosis is PNI positive or negative.
[0072] S2. Experimental steps: paraffin sectioning, dewaxing and hydration, antigen retrieval, inactivation of endogenous peroxidase, blocking, antibody incubation and DAB color development / counter staining.
[0073] S3. Film review and scoring:
[0074] Cell staining intensity integration: Under a 10x microscope, 5 fields of view / slide were randomly selected, and the average integration of the 5 fields of view was taken, and the result was retained to 1 decimal place.
[0075] Table 3. Cell staining intensity and scoring results
[0076] Coloring Expression score No coloring Negative 0 Light yellow Weak positive 1 Brown Moderately positive 2 Brownish yellow Strong positive 3
[0077] Percentage of positive (including weakly positive, moderately positive and strongly positive) cells: Observe the sections under a 4x microscope to evaluate the percentage of positive cells in the total number of cells.
[0078] The positive grade of section staining = cell staining intensity score * percentage of positive cell expression, and the data were analyzed using GraPhPad Prism software.
[0079] S4. Experimental results:
[0080] IHC staining of CNB1 was performed on samples from 22 patients with negative and 26 patients with positive AHJU gastric cancer perineural invasion. Figure 6 A is the IHC staining image of PNI samples (including negative PNI- and positive PNI+). The enlarged part shows that tumor cells surround the neural tube. Figure 6 The IHC staining score shown in B demonstrated that PPP3R1 was more highly expressed in gastric cancer PNI-negative than in gastric cancer PNI-positive, p=0.0073.
[0081] Embodiment 3:
[0082] In vitro experiments verified the correlation between PPP3R1 and gastric cancer nerve invasion, including the following technical steps:
[0083] S1. Cell lines and animals:
[0084] Mouse gastric cancer cell line MFC cells (purchased from Wuhan Pronocell Life Science Co., Ltd.), 8-day-old SD rats (any gender, purchased from Jiangsu University Animal Experiment Center).
[0085] S2. Construction of cell lines with knockdown of PPP3R1 by viral infection of gastric cancer cells:
[0086] (1) Transfection virus sequence:
[0087] The cell transfection experiment was divided into two groups: shNC group (negative control group) and shPPP3R1 group (transfection group). The transfection virus sequences were as follows:
[0088] Table 4. Transfection virus sequences
[0089] name Sequence (5'--3') shNC (SEQ ID No: 4) TTCTCCGAACGTGTCACGT shPPP3R1(human)(SEQ ID No: 5) TACAATTTGCGCCAGGTATTA shPPP3R1(mouse)(SEQ ID No: 6) TACAATTTGCGCCAGGTATTA
[0090] (2) Infection experiment steps:
[0091] Prepare complete culture medium: add 45 mL RPMI 1640 culture medium (purchased from Gibco), 5 mL fetal bovine serum (purchased from Beijing Quanshijin Biotechnology Co., Ltd.), and 500 μL penicillin-streptomycin solution (purchased from Gibco) into a 50 mL EP tube, cover the tube with a sealing film, and place it in a 4°C refrigerator.
[0092] The present invention mainly constructs two types of lentiviruses, one is a lentivirus with shNC sequence as the target sequence, which serves as a negative control group, and the other is a lentivirus with shPPP3R1 (mouse) sequence as the target sequence, which serves as an experimental group. Both lentiviruses are constructed by a third-generation lentiviral vector system (all known public vectors are acceptable).
[0093] The MFC gastric cancer cell suspension was inoculated on a 6-well plate. The optimal virus infection multiplicity (MOI) of MFC cells was verified to be 10 by pre-transfection experiments. The volume of virus to be added was calculated as (MOI × number of cells) / virus titer. After 24 hours, 1 mL of RPMI 1640 medium + HiTransG 40 μL of P infection solution (purchased from Shanghai Jikai Gene Medical Technology Co., Ltd.) + lentivirus were added to the 6-well plate of cultured MFC; after culturing for 12 hours, the complete culture medium was replaced, and after 48-72 hours of infection, the fluorescence signal of the cells was detected under a fluorescence microscope to evaluate the transfection effect; a T25 culture flask with 5 mL of complete culture medium was prepared, and when the cell density reached 80%, after rinsing, digestion, resuspension, centrifugation and resuspension, the cells were resuspended in complete culture medium with 0.5 μL / 1 mL of puromycin added, and all were inoculated into a T25 culture flask with 4 mL of complete culture medium, and the cell adhesion was observed after culturing at 37°C for 24 hours; the culture medium and the suspended cells therein were removed, and when the cells grew to about 80%, the puromycin concentration was gradually increased according to the cell state to screen out the gastric cancer cells that were not successfully transfected; the amount of puromycin was gradually increased until there was no obvious cell suspension and the fluorescence signal under the fluorescence microscope reached more than 90%, and then normal passage and cryopreservation were performed.
[0094] (3) Protein extraction:
[0095] The screened MFC cells were subjected to cell lysis, high-speed centrifugation, supernatant aspiration, protein concentration measurement, buffer resuspending, and protein boiling to obtain the target protein.
[0096] (4) Western Blot experiment:
[0097] The target protein extracted in step (3) was subjected to the following operations: preparing separation gel and concentration gel, loading samples, transferring to membrane, blocking, incubating with primary antibody, washing with TBST, incubating with secondary antibody, washing with TBST, and exposing to light, to obtain the target band. The band was quantitatively analyzed using image J software.
[0098] (5) Experimental results:
[0099] The mouse gastric cancer cell line MFC was transfected with virus. Under a fluorescence microscope, it was observed that the virus transfection efficiency reached more than 90% after puromycin selection ( Figure 7 A). Proteins were extracted from the screened shNC and shPPP3R1 group MFC cells, and WB experiments were performed ( Figure 7 B), quantitative analysis of WB results showed that the PPP3R1 gene was significantly knocked down (p = 0.013, Figure 7 C). The above results indicate that the MFC gastric cancer cell line with PPP3R1 knockdown was successfully constructed.
[0100] S3. Dorsal root ganglion (DRG)-gastric cancer cell co-culture in vitro:
[0101] (1) Required reagents and preparation methods:
[0102] a. 200 mM L-glutamine: Weigh 116.8 mg of L-glutamine powder using an electronic balance, dissolve it thoroughly with 4 mL of PBS, mix well using a vortex oscillator, and store at -20°C.
[0103] b. 0.1 mg / mL poly-lysine: Dispense 80 μL of the reagent into 5 mL EP tubes and store at -20°C. Take one tube and add it to 4 mL PBS for immediate use.
[0104] c. 1 mg / mL type I collagenase: Weigh 10 mg of type I collagenase powder, add 8 mL of PBS to fully dissolve, then add PBS to make up to 10 mL, divide the prepared solution into 2 mL per tube, mark each tube, and store at -20°C.
[0105] d. Low growth factor matrix gel: Divide Matrigel into 100 μL per tube in advance and prepare it according to PBS:Matrigel=1:2 during the experiment. Prepare and use it immediately and operate on ice throughout the process.
[0106] e. DRG culture medium: Add 500 μL 1% double antibody (purchased from Gibco), 500 μL 200 mM l-glutamine (purchased from Solebol), 1 mL STEMCELL modified neuronal supplement (purchased from stem cell), and 25 μL 50 ng / mL nerve growth factor (purchased from Gibco) to 48 mL Neurobasal-A culture medium (purchased from Gibco).
[0107] (2) Co-cultivation steps:
[0108] a.PLL plating: 1 mL of polylysine (PLL) was evenly spread in a 6-well plate, and allowed to stand overnight at room temperature. The next day, excess liquid was removed. PBS was added, and the plate was rinsed three times. After treatment, the plate was sterile and dried for later use;
[0109] b. Extraction of DRG: After killing 8-day-old SD rats with CO2, cut off the head of the rat, separate the back layer by layer, remove the spine, and cut off excess muscle and tissue; put the spine on ice, cut it into two sections, and use a 10mL syringe connected to a yellow gun tip to absorb PBS to flush out the spinal cord, then cut the spine longitudinally in the middle, and use micro forceps and micro scissors to separate DRG under a stereomicroscope. Be careful not to damage DRG during the separation process, and temporarily place the separated DRG in the prepared DRG culture medium.
[0110] c. Initial digestion: After washing away excess tissue and blood cells with pre-cooled PBS, add 2 mL of type I collagenase for initial digestion for 30 minutes, and wash again with PBS. This process must be careful and gentle to prevent the DRG from being washed away. The processed DRG is temporarily placed in DRG culture medium.
[0111] d. Seed plate: The following operations must be performed on ice. 5 MFC cells were resuspended in 20 μL low growth factor Matrigel and seeded in the center of a 6-well plate. 20 μL of Matrigel was added to the left side of the cells, and DRG was gently placed in the center (about 500 μm away from the edge of the cells). 20 μL of Matrigel was added to the right side of the cells as a blank control and placed in a 37°C incubator for 30 min.
[0112] e. Culture and photography: Add 2 mL of DRG complete culture medium and culture in a 37°C incubator. Change the culture medium every 2 days. Take photos every day under a 4x microscope to record the movement distance of cells and DRGs, and analyze the results using imageJ software and GraPhPad Prism software.
[0113] S4. Immunofluorescence staining of DRG
[0114] (1) Required reagents and preparation methods:
[0115] 0.02% PBST: Add 50 mL PBS to a 50 mL EP tube, then add 10 μL Tween and mix well using a vortex oscillator.
[0116] (2) Experimental steps:
[0117] a.PLL plating: 1 mL of polylysine (PLL) was evenly spread in a 6-well plate, and allowed to stand overnight at room temperature. The next day, excess liquid was removed. PBS was added, and the plate was rinsed three times. After treatment, the plate was sterile and dried for later use;
[0118] b. Extraction of DRG: After killing 8-day-old SD rats with CO2, cut off the head of the rat, separate the back layer by layer, remove the spine, and cut off excess muscle and tissue; put the spine on ice, cut it into two sections, and use a 10mL syringe connected to a yellow gun tip to absorb PBS to flush out the spinal cord, then cut the spine longitudinally in the middle, and use micro forceps and micro scissors to separate DRG under a stereomicroscope. Be careful not to damage DRG during the separation process, and temporarily place the separated DRG in the prepared DRG culture medium.
[0119] c. Initial digestion: After washing away excess tissue and blood cells with pre-cooled PBS, add 2 mL of type I collagenase for initial digestion for 30 minutes, and wash again with PBS. This process must be careful and gentle to prevent the DRG from being washed away. The processed DRG is temporarily placed in DRG culture medium.
[0120] d. Add 20 μL of matrix gel to a 6-well plate, gently place the DRG in the center, and incubate at 37°C for 30 min. Add 2 mL of DRG culture medium and place in a 37°C incubator.
[0121] e. Cell fixation and staining: After 24 hours of culture, discard the culture medium, add 1 mL of PBS to rinse twice, then add 1 mL of 4% paraformaldehyde to fix for 20 min, discard the fixative, and add 1 mL of PBS to rinse 3 times, each time for 2 min.
[0122] f. Cell permeabilization: Add 1 mL TritonX-100 to a 6-well plate and permeabilize for 10 min at room temperature.
[0123] g. Blocking: After absorbing the permeabilization solution, rinse with PBST three times, 5 minutes each time, and block with immunostaining blocking solution (purchased from Bio-Time) at room temperature for 15 minutes. The liquid must completely cover the DRG and the slides must not dry out.
[0124] h. Antibody incubation: According to the corresponding instructions, prepare rabbit anti-rat S100β antibody (Abcam (USA)), mouse anti-rat βⅢTublin antibody (Abcam (USA)), Cy3-labeled goat anti-mouse secondary antibody (Biyuntian Biotechnology Co., Ltd.) and AMCA-labeled goat anti-rabbit secondary antibody solution (Wuhan Sanying Biotechnology Co., Ltd.). Add the prepared primary antibody solution to a 6-well plate, completely cover the DRG, and incubate overnight at room temperature. Recover the primary antibody and rinse with PBST 3 times, 5 minutes each time. Add the prepared secondary antibody solution to a 6-well plate, cover the DRG, and incubate at room temperature for 4 hours. Recover the secondary antibody and rinse with PBST 3 times, 5 minutes each time.
[0125] i. Observe in the dark: drop antifade agent onto the surface of DRG and take pictures under a fluorescence microscope in the dark.
[0126] (3) Analyze data:
[0127] The distance between DRG and tumor cells at 0h and the migration distance of DRG and tumor cells in the control group and experimental group at 96h were measured and recorded using imageJ software. The tumor invasion index = 96h tumor cell movement distance / 0h DRG and tumor cell distance, and the DRG growth index = 96h DRG axon growth distance / 0h DRG and tumor cell distance. Finally, GraPhPadPrism software was used to analyze the results.
[0128] (4) Experimental results:
[0129] DRGs were extracted from 8-day-old SD rats. After DRGs were grown in matrix gel for 24 hours, immunofluorescence staining of S100β and βⅢTublin showed strong positive staining results, and the newly generated neurofilaments of DRGs also showed positive staining, that is, the tissue extracted from the rat spine was DRG, and the DRGs were in good growth condition ( Figure 8 ).
[0130] Construct an in vitro DRG and MFC co-culture model, as shown in the figure Fig. 9 As shown, the middle is tumor cells, the left is DRG, and the right is low growth factor matrix gel as a blank control. After the model was successfully constructed, it was seen that tumor cells and DRG grew in opposite directions, and the migration distance of the shPPP3R1 group was significantly increased compared with the shNC group at 0, 48 and 96 hours ( Fig.10 A), Statistical analysis of tumor cell invasion and DRG migration results showed that after knocking down PPP3R1, the invasion ability of tumor cells into DRG was significantly enhanced, and the growth rate of DRG into tumor cells was significantly accelerated (p < 0.05) ( Fig.10 B). Under 20x and 40x microscopes, we can see that the tumor cells MFC with GFP green fluorescence after virus transfection invade the roots of DRG ( Fig.11The above results show that knocking down PPP3R1 enhances the invasion ability of gastric cancer cells into DRG, and knocking down PPP3R1 can promote the growth of DRG, indicating that the invasion of gastric cancer cells and the growth of DRG jointly lead to the neural invasion of tumor cells, and also indicate that PPP3R1 plays an important role in inhibiting the neural invasion of gastric cancer.
[0131] Embodiment 4:
[0132] In vivo experiments verified the correlation between PPP3R1 and gastric cancer nerve invasion, including the following technical steps:
[0133] S1. Experimental steps:
[0134] a. Nude mice (purchased from Cavens Laboratory Animal Co., Ltd.) were randomly divided into three groups in advance, namely, control group, shNC group, and shPPP3R1 group. Before surgery, nude mice were anesthetized by inhalation of isoflurane gas, and anesthesia was confirmed by no movement of the limbs, no reaction to the whiskers being touched, and no reaction to the foot pinching stimulation.
[0135] The shNC group and the shPPP3R1 group were injected with MFC gastric cancer cells transfected with lentivirus, and the control group was injected with an equal amount of PBS; the target sequence of the lentivirus transfected with the shNC group was the shNC sequence, and the target sequence of the lentivirus transfected with the shPPP3R1 group was the shPPP3R1 sequence.
[0136] b. Under anesthesia, fix the limbs of the nude mouse with hypoallergenic tape and disinfect with iodine.
[0137] c. Use a scalpel to make a 1 cm incision 2 mm below the femur and parallel to the femur. Use forceps to retract the skin outward to expose the deep muscles.
[0138] d. Use forceps to separate the deep muscles along the fascial plane to expose the sciatic nerve underneath. Use blunt dissection to separate the nerve from the surrounding muscles.
[0139] e. Use a 10μL Hamilton precision syringe to draw PBS to confirm that the syringe is unobstructed and leak-free. The density of the MFC gastric cancer cell suspension is 1×10 4 / μL, take 5μL of gastric cancer cell suspension into a 10μL Hamilton syringe.
[0140] f. Be very careful when injecting to avoid puncturing the posterior wall of the nerve, which would lead to the loss of cancer cells. Inject gastric cancer cells from the inside to the outside (from the spine to the tibial end) at the level of the middle section of the sciatic nerve. The injection should be performed at a slow and steady pace, injecting 1 μL of MCF gastric cancer cell suspension into the sciatic nerve. The injection time should exceed 5 seconds to prevent pressure from pushing the gastric cancer cells forward from the injection point.
[0141] g. Leave the needle on the nerve for another 3 seconds after injection to reduce backflow and cancer cell leakage.
[0142] h. Reposition the nerve, suture the skin with 4-0 sutures and disinfect.
[0143] i. Place the mouse individually in a clean cage and observe the recovery process until it recovers.
[0144] S2. Evaluation of neurological function invasion indicators in mice:
[0145] a. Evaluate sciatic nerve function score every 4 days
[0146] Table 5. Sciatic nerve function scores
[0147] Fraction Sciatic nerve function score 4 Completely normal 3 Able to resist resistance, limited motor function 2 Partial paralysis, can resist gravity but not resistance 1 Completely paralyzed, unable to resist gravity or resistance
[0148] b. Assess the sciatic nerve function index every 4 days
[0149] When the mouse was standing on all fours, the extension length (mm) between the first toe and the fifth toe of the left lower limb of the mouse was measured with a vernier caliper, and the average value was taken after three measurements.
[0150] c. Tumor volume measurement: After the tumor is formed, the volume is measured with a vernier caliper every 4 days. The tumor volume is calculated according to the formula for calculating the subcutaneous tumor volume: V = 1 / 2*a*b2 (a is the long axis, b is the short axis)
[0151] d. Tumor weight measurement: On the 20th day after tumor cell injection, the mouse tumors were dissected and the tumor weights of the shNC group and shPPP3R1 group were weighed.
[0152] e. Immunohistochemistry: The dissected mouse tumors were subjected to immunohistochemistry and other procedures, observed under a microscope, and photographed and recorded.
[0153] S3. Experimental results:
[0154] In this study, an in vivo model of tumor invasion of nerves was constructed. It was found that on the 20th day, the sciatic nerve function of mice injected with PBS in the control group did not change significantly compared with that before surgery, while the sciatic nerve function of mice injected with shPPP3R1-MFC was significantly limited compared with that of the shNC-MFC group, as manifested by decreased muscle strength, significantly shortened distance between the five fingers of the left hind limb, and increased tumor volume. In the immunohistochemical sections of tumor tissues of both groups of mice, tumor cells invading the nerves were observed ( Fig.12 ). On the 20th day after the injection of MFC, the tumor tissue of the mice was peeled off. It was visible to the naked eye that after the knockdown of PPP3R1, the tumor tissue was significantly larger than that of the control group, and the growth rate was significantly accelerated ( Fig.13). According to the evaluation index of sciatic nerve function of mice, it can be found that the sciatic nerve function score of shPPP3R1 group mice is higher than that of shNC group mice ( Fig.14 A, p = 0.0414) and sciatic nerve function index ( Fig.14 B, p = 0.0456) decreased significantly, and the tumor volume of mice ( Fig.14 C, p = 0.0333) and tumor weight increased significantly ( Fig.14 D, p = 0.0041); indicating that PPP3R1 has important value in predicting the incidence of perineural invasion (PNI) and overall survival of GC patients, and can be used as a molecular marker for perineural invasion of gastric cancer.
[0155] The nucleotide sequence of the PPP3R1 gene of the present invention is shown in SEQ ID No: 1:
[0156]
Claims
1. A PPP3R1 gene related to gastric cancer nerve invasion, characterized in that: The nucleotide sequence of the PPP3R1 gene is shown in SEQ ID No:
1.
2. A molecular marker related to gastric cancer nerve invasion, characterized in that: The molecular marker includes the PPP3R1 gene, and the nucleotide sequence of the PPP3R1 gene is shown in SEQ ID No:
1.
3. The PPP3R1 gene according to claim 1 or the molecular marker according to claim 2, characterized in that: The nucleotide sequence of the mRNA of the PPP3R1 gene is shown in SEQ ID No: 2; the amino acid sequence of the protein encoded by the PPP3R1 gene is shown in SEQ ID No:
3.
4. A reagent for detecting the PPP3R1 gene according to claim 1 or the molecular marker according to claim 2.
5. Use of the gene according to claim 1, the molecular marker according to claim 2 or the reagent according to claim 4 in the preparation of a product for diagnosis, detection and prognosis of gastric cancer nerve invasion, wherein the product comprises a kit.
6. The use according to claim 5, characterized in that: The prognosis is judged as follows: the higher the expression level of the PPP3R1 gene, the better the prognosis of gastric cancer.
7. Use of the gene according to claim 1, the molecular marker according to claim 2 or the reagent according to claim 4 in the preparation of a product for treating gastric cancer neural invasion.
8. Use of an agent for inhibiting or knocking down the expression of the PPP3R1 gene according to claim 1 or the molecular marker according to claim 2 in preparing an in vitro neural invasion model, wherein the agent is shRNA, and the nucleotide sequence of the shRNA is shown in SEQ ID No:
5.
9. A product for diagnosing, detecting and prognosing gastric cancer nerve invasion, characterized in that: The product comprises a reagent for detecting the PPP3R1 gene according to claim 1 or a molecular marker according to claim 2.
10. A product for treating gastric cancer nerve invasion, characterized in that: The product comprises a reagent for detecting the PPP3R1 gene according to claim 1 or a molecular marker according to claim 2.
